Amgen
FDA Approves Nivestym, Second Biosimilar of Neupogen
The FDA approved Pfizer's Nivestym, a biosimilar of Neupogen for all eligible indications as the reference ...
JULY 25, 2018
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 6, 2018
First Epoetin alfa Biosimilar Receives FDA Approval for Anemia
Retacrit is the first U.S. biosimilar erythropoiesis-stimulating agent. Although not listed as an interchangeable ...
MAY 21, 2018
FDA Approves Blincyto for ALL Pts with Minimal Residual Disease
Blincyto is the first and only FDA-approved therapy for patients who have ALL that is in remission but who still ...
MARCH 29, 2018
Load more